BMY acquires KRTX for $330/sh cash—a 53% premium to Thursday’s close: https://finance.yahoo.com/news/bristol-myers-squibb-strengthens-neuroscience-120500513.html The nominal deal value is $14B; after deducting KRTX’s $1.3B of net cash, the equity value is $12.7B.